Research programme: antibody therapeutics - Innovative Targeting Solutions/Sanofi
Latest Information Update: 28 Jun 2022
At a glance
- Originator Innovative Targeting Solutions; Sanofi
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for research development in Unspecified in Canada
- 28 Jun 2022 No recent reports of development identified for research development in Unspecified in France
- 21 Oct 2019 Innovative Targeting Solutions has patent protection for HuTARG platform in Europe